Homotyrosine, (+)- | CAS#221243-01-2 | sodium channel blocker

MedKoo Cat#: 597358 | Name: Homotyrosine, (+)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Homotyrosine, (+)- is an amino acid; a very stable, selective and renally safe sodium channel blocker.

Chemical Structure

Homotyrosine, (+)-

CAS#221243-01-2

Theoretical Analysis

MedKoo Cat#: 597358

Name: Homotyrosine, (+)-

CAS#: 221243-01-2

Chemical Formula: C10H13NO3

Exact Mass: 195.0895

Molecular Weight: 195.21

Elemental Analysis: C, 61.53; H, 6.71; N, 7.18; O, 24.59

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Homotyrosine, (+)-; L-Homotyrosine; alpha-Homotyrosine, (+)-;

IUPAC/Chemical Name

(S)-2-amino-4-(4-hydroxyphenyl)butanoic acid

InChi Key

LOOZZTFGSTZNRX-VIFPVBQESA-N

InChi Code

InChI=1S/C10H13NO3/c11-9(10(13)14)6-3-7-1-4-8(12)5-2-7/h1-2,4-5,9,12H,3,6,11H2,(H,13,14)/t9-/m0/s1

SMILES Code

O=C(O)[C@@H](N)CCC1=CC=C(O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 195.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Radha Rama Devi A, Naushad SM. SLC25A13 c.1610_1612delinsAT mutation in an Indian patient and literature review of 79 cases of citrin deficiency for genotype-phenotype associations. Gene. 2018 Aug 20;668:190-195. doi: 10.1016/j.gene.2018.05.076. Epub 2018 May 19. Review. PubMed PMID: 29787821. 2: Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev. 2018 Jun;67:71-77. doi: 10.1016/j.ctrv.2018.05.004. Epub 2018 May 9. Review. PubMed PMID: 29772459. 3: Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M, Prat A. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treat Rev. 2018 Jun;67:63-70. doi: 10.1016/j.ctrv.2018.04.015. Epub 2018 May 7. Review. PubMed PMID: 29763779. 4: Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M, Cassagnol M, Camenisch TD, Anwer F, Hollands JM. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018 Jun;126:186-200. doi: 10.1016/j.critrevonc.2018.03.014. Epub 2018 Mar 29. Review. PubMed PMID: 29759560. 5: El Rassy E, Pavlidis N. The current evidence for a biomarker-based approach in cancer of unknown primary. Cancer Treat Rev. 2018 Jun;67:21-28. doi: 10.1016/j.ctrv.2018.04.011. Epub 2018 May 2. Review. PubMed PMID: 29751335. 6: Kerru N, Singh-Pillay A, Awolade P, Singh P. Current anti-diabetic agents and their molecular targets: A review. Eur J Med Chem. 2018 May 25;152:436-488. doi: 10.1016/j.ejmech.2018.04.061. Epub 2018 May 3. Review. PubMed PMID: 29751237. 7: Liao BC, Lin CC, Yang JC. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018 Jun;19(8):851-864. doi: 10.1080/14656566.2018.1472765. Epub 2018 May 22. Review. PubMed PMID: 29726292. 8: Shah MA, Keach JE, Panichayupakaranant P. Antidiabetic Naphthoquinones and Their Plant Resources in Thailand. Chem Pharm Bull (Tokyo). 2018;66(5):483-492. doi: 10.1248/cpb.c17-00529. Review. PubMed PMID: 29710045. 9: Levy A, Doyen J. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. Crit Rev Oncol Hematol. 2018 May;125:41-47. doi: 10.1016/j.critrevonc.2018.03.001. Epub 2018 Mar 6. Review. PubMed PMID: 29650275. 10: Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, Thareja S. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem. 2018 May 10;151:315-326. doi: 10.1016/j.ejmech.2018.03.062. Epub 2018 Mar 23. Review. PubMed PMID: 29631132. 11: Yu J, Zheng J, Xu W, Weng J, Gao L, Tao L, Liang F, Zhang J. Accuracy of (18)F-FDOPA Positron Emission Tomography and (18)F-FET Positron Emission Tomography for Differentiating Radiation Necrosis from Brain Tumor Recurrence. World Neurosurg. 2018 Jun;114:e1211-e1224. doi: 10.1016/j.wneu.2018.03.179. Epub 2018 Apr 4. Review. PubMed PMID: 29625311. 12: Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2018 Apr;27(4):363-375. doi: 10.1080/13543784.2018.1462336. Epub 2018 Apr 11. Review. PubMed PMID: 29621416. 13: Bartaula-Brevik S, Lindstad Brattås MK, Tvedt THA, Reikvam H, Bruserud Ø. Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. Expert Opin Investig Drugs. 2018 Apr;27(4):377-387. doi: 10.1080/13543784.2018.1459562. Epub 2018 Apr 4. Review. PubMed PMID: 29611449. 14: Lewandowska K. [Nintedanib in the treatment of fibrosing interstital lung diseases]. Pol Merkur Lekarski. 2018 Mar 27;44(261):139-141. Review. Polish. PubMed PMID: 29601564. 15: Apostolou KG, Schizas D, Vavouraki E, Michalinos A, Tsilimigras DI, Garmpis N, Damaskos C, Papalampros A, Liakakos T. Clinicopathological and Molecular Factors, Risk Factors, Treatment Outcomes and Risk of Recurrence in Mesenteric and Retroperitoneal Extragastrointestinal Stromal Tumors. Anticancer Res. 2018 Apr;38(4):1903-1909. Review. PubMed PMID: 29599305. 16: Concu R, Cordeiro MNDS. Looking for New Inhibitors for the Epidermal Growth Factor Receptor. Curr Top Med Chem. 2018;18(3):219-232. doi: 10.2174/1568026618666180329123023. Review. PubMed PMID: 29595111. 17: De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):461-467. doi: 10.1080/17425255.2018.1455826. Epub 2018 Mar 23. Review. PubMed PMID: 29557694. 18: Lao QY, Sun M, Yu L, Wang J. [Lipofibromatosis: a clinicopathological analysis of eight cases]. Zhonghua Bing Li Xue Za Zhi. 2018 Mar 8;47(3):186-191. doi: 10.3760/cma.j.issn.0529-5807.2018.03.008. Review. Chinese. PubMed PMID: 29534358. 19: Wendołowicz A, Stefańska E, Ostrowska L. Influence of selected dietary components on the functioning of the human nervous system. Rocz Panstw Zakl Hig. 2018;69(1):15-21. Review. PubMed PMID: 29517182. 20: Albin N, Mc Leer A, Sakhri L. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?]. Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1. Review. French. PubMed PMID: 29501208.